Johnson & Johnson

04/26/2024 | Press release | Distributed by Public on 04/26/2024 08:19

Johnson & Johnson receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small[...]